Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Fusion

Fusion

CIViC ID: 1278 · Gene: LMNA::NTRK1

Variant Summary

Also known as: LMNA-NTRK1
HGVS: —
Variant Type(s): transcript_fusion
Evidence Items: 19

Evidence Level Distribution

Level C: 13Level D: 6

Evidence Items

Showing CIViC evidence rows where gene = LMNA::NTRK1 and variant = Fusion.

Level	Type	Direction	Significance	Disease	Drugs	Rating
C	Diagnostic	Supports	Positive	Lipofibromatosis-like Neural Tumor		4
C	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Entrectinib	4
D	Predictive	Supports	Sensitivity/Response	Cancer	Entrectinib	3
D	Predictive	Supports	Sensitivity/Response	Cancer	Repotrectinib	3
D	Predictive	Supports	Sensitivity/Response	Cancer	Entrectinib	3
C	Diagnostic	Supports	Positive	Lipofibromatosis-like Neural Tumor		3
C	Diagnostic	Supports	Positive	Lipofibromatosis-like Neural Tumor		3
C	Predictive	Supports	Sensitivity/Response	Lipofibromatosis-like Neural Tumor	Entrectinib	3
C	Diagnostic	Supports	Positive	Lipofibromatosis-like Neural Tumor		3
C	Predictive	Supports	Sensitivity/Response	Colorectal Adenocarcinoma	Entrectinib	3
C	Predictive	Supports	Sensitivity/Response	Sarcoma	Larotrectinib	3
C	Predictive	Supports	Sensitivity/Response	Congenital Fibrosarcoma	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Spindle Cell Sarcoma	TRK Inhibitor	3
D	Oncogenic	Supports	Oncogenicity	Spitzoid Melanoma		3
C	Diagnostic	Supports	Positive	Spitzoid Melanoma		3
C	Predictive	Supports	Sensitivity/Response	Solid Tumor	Larotrectinib	3
D	Predictive	Supports	Sensitivity/Response	Cancer	Larotrectinib	2
C	Predictive	Supports	Sensitivity/Response	Sarcoma	Larotrectinib	2
D	Oncogenic	Supports	Oncogenicity	Colorectal Cancer		1